Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.70 |
| ▸ | DRD4 | P21917 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350053 | 0.83 | DRD4 (0.73) | HTR1ADRD4DRD2KDM4E | |
| SCHEMBL6350184 | 0.82 | DRD4 (0.72) | HTR1ADRD4DRD2ALDH1A1KDM4E | |
| SCHEMBL6350180 | 0.82 | DRD4 (0.72) | HTR1ADRD4DRD2ALDH1A1KDM4E | |
| SCHEMBL16026463 | 0.81 | KMT2A (0.83) | HTR1AALDH1A1KMT2AGFERMAPT | |
| SCHEMBL17549635 | 0.81 | ALDH1A1 (0.79) | HTR1AALDH1A1KMT2AGFERKDM4E | |
| SCHEMBL4687871 | 0.81 | DRD2 (0.58) | HTR1ADRD4DRD2 | |
| SCHEMBL4935832 | 0.81 | DRD2 (0.58) | HTR1ADRD4DRD2 | |
| SCHEMBL3196213 | 0.80 | DRD2 (0.57) | HTR1ADRD4DRD2 | |
| Hydrochloric Acid SCHEMBL7934846 | 0.80 | KMT2A (0.83) | HTR1AALDH1A1KMT2AGFERLMNA | |
| SCHEMBL351997 | 0.79 | HTR1A (0.81) | HTR1ADRD2ALDH1A1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | HTR1A 871/4885DRD4 1272/4885DRD2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.